Interestingly, serum IL-1α and IL-1β levels seem to be of prognostic value as they predicted ACLF development in patients with compensated and decompensated cirrhosis, respectively.109 It remains to be studied if lower vs. higher NLRP3 inflammasome activation in the liver or in the systemic circulation correlates with subsequent fibrosis regression vs. stabilization/progression, and if inflammasome-related read-outs may serve as ‘dynamic’ biomarkers allowing for the prediction of liver-related events. The gene discussed is IL1A; the disease is Cirrhosis.